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p53, p63 and p73 are members of the p53 gene family involved in development, differentiation and response to cellular stress. p53
gene is a transcription factor essential for the prevention of cancer formation. The p53 pathway is ubiquitously lost in human cancer
either by p53 gene mutation (60% of cancers) or by lost of cell signalling upstream and downstream of p53 in the remaining cancers
expressing WTp53 gene. As p53 pathway inactivation is a common denominator to all cancers, the understanding of p53 tumour
suppressor activity is likely to bring us closer to cancer therapy. However, despite all the experimental evidences showing the
importance of p53 in preventing carcinogenesis, it is difficult in clinical studies to link p53 status to cancer treatment and clinical
outcome. The recent discovery that p53 gene encodes for nine different p53 proteins (isoforms) may have a profound impact on our
understanding of p53 tumour suppressor activity. Studies in several tumour types have shown that the nine different p53 isoforms are
abnormally expressed in tumour tissues compared to normal cells. p53 protein isoforms modulate p53 transcriptional activity and cell
fate outcome in response to stress. Regulation of p53 function in normal and tumour tissues in man is likely to be more complex than
has been hitherto appreciated. Therefore, the tumour p53 status needs to be determined more accurately by integrating p53 isoform
expression, functional p53 mutation analysis and a panel of antibodies specific of p53 and of its target genes.
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The response to cellular damage is complex involving the
recognition of the damages and repair of the lesions, in particular,
DNA damages to minimise the risk of genetic instability. There-
fore, mutations or alterations of protein expression involved in
this process predispose to genome instability, cancer and other
pathologies (Kops et al, 2005). A central player in protecting the
integrity of the genome is p53. The importance of its role is
exemplified by the facts that p53 activity is ubiquitously lost in
human cancer either by p53 protein inactivation or by p53 gene
mutation (for a review, see Iwakuma and Lozano, 2007; Lozano,
2007; Petitjean et al, 2007a; Vousden and Lane, 2007).
p53 protein is expressed at low levels under unperturbed
conditions. However, the p53 pathway is activated by any cellular
stresses that alter the normal cell-cycle progression or can induce
mutations of the genome leading to the transformation of a normal
cell into a cancerous cell. Depending on the tissue-type and the
extend of the damage, activated p53 protein either stops the cell
cycle to repair the lesions or switches ‘on’ the programmed cell
death pathways (apoptosis), forcing the damaged cells to ‘commit
suicide’. The p53 protein prevents the multiplication of damaged
cells that are more likely to contain mutations and exhibit
abnormal cellular growth than undamaged cells. Hence, p53
protein is the guardian of the genome preventing cancer formation
(Lane, 1992).
The mechanisms by which p53 accomplishes its tumour
suppressor activity are still not completely understood. The best-
described mechanism is its ability to modulate gene expression.
p53 is a transcription factor that binds directly and specifically as a
tetramer to target sequences of DNA (p53-responsive elements
(p53RE)) (El-Deiry et al, 1992; Funk et al, 1992; Bourdon et al,
1997). The ability of p53 to modulate gene expression is required
for its tumour suppressor activity. Identification of the cyclin-
dependent kinase inhibitor Waf as a p53-responsive gene, helps to
explain how p53 can induce cell-cycle arrest (El-Deiry et al, 1993;
Harper et al, 1993). Recently, several p53-inducible genes that
encode for proteins with apoptotic potential have been identified
(Chipuk and Green, 2006). However, the tumour suppressor p53
can trigger cell death independently of its transcriptional activity
through subcellular translocation and activation of proapoptotic
Bcl-2 family members (Moll et al, 2005).
HUMAN p63 AND p73 ISOFORMS
Two p53-related genes, p63 and p73, were identified in 1997
(Kaghad et al, 1997; Yang et al, 1998). The high level of sequence
similarity in the DNA-binding domain between p53 protein family
members allows p63 and p73 to transactivate p53-responsive genes
causing cell-cycle arrest and apoptosis. However, p53, p63 and p73
proteins are not entirely functionally redundant as each p53-family
transgenic knockout mice develop distinct phenotypes, illustrating
that p53, p63 and p73 have specific biological functions (for a
review, see Murray-Zmijewski et al, 2006).
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has a dual gene structure conserved in Drosophila, zebrafish and
man (Bourdon et al, 2005; Chen et al, 2005). Like most of the genes
in the human genome (Stamm et al, 2005), p53 gene family
members express multiple mRNA variants due to multiple splicing
and alternative promoters. Hence, p53 gene family members
express different forms of p53 protein containing different domain
of the protein (isoforms).
The human and mouse p63 genes express at least three
alternatively spliced C-terminal isoforms (a, b, g) and can be
transcribed from an alternative promoter located in the intron 3
(Figure 1A). The transactivating isoforms (TAp63) are generated
by the promoter upstream of exon-1, whereas the alternative
promoter in intron 3 leads to the expression of N-terminal-
truncated p63 isoforms (DNp63) containing a different N-terminal
domain. Altogether, the p63 gene expresses at least six mRNA
variants which encode for six different p63 protein isoforms
(TAp63a, TAp63b, TAp63g, DNp63a, DNp63b and DNp63g).
Although DNp63 isoforms lack the transactivation domain present
in TAp63 isoform, they can transactivate through a different
transactivation domain present in their distinct N-terminal end
(Helton et al, 2006) (Figure 1B). p63 isoforms are able to bind to
DNA through p53RE and p63RE to regulate transcription of target
genes involved in differentiation, cell-cycle arrest or apoptosis
(Murray-Zmijewski et al, 2006; Stiewe, 2007). Genetic experiments
on mice have shown that p63 is essential for epidermal
morphogenesis and limb development. p63-null animals do not
survive beyond a few days after birth, show craniofacial
malformations, limb truncations and fail to develop skin and
other epithelial tissues (Mills et al, 1999).
Like p63, the p73 gene can be transcribed from an alternative
promoter located in the intron 3 (Figure 2A). The p73 gene
expresses at least seven alternatively spliced C-terminal isoforms
(a, b, g, D, e, z, Z) and at least four alternatively spliced N-terminal
isoforms, which contain different parts of the transactivation
domain. Altogether, the p73 gene expresses at least 35 mRNA
variants, which can encode theoretically 29 different p73 protein
isoforms (Figure 2B). p73 isoforms encoded by alternatively
spliced exon2 and/or exon-3 mRNA variants are initiated at
different ATG and contain therefore different part of the N-
terminal domain, suggesting that they can have distinct protein
interactions and specific activities. p73 isoforms are able to bind
specically to DNA through p53RE and p73RE and activate
transcription of target genes. Like p53, such activation can induce
cell-cycle arrest or apoptosis (Murray-Zmijewski et al, 2006;
Stiewe, 2007). Mice, functionally decient for all p73 isoforms,
exhibited profound defects, including hippocampal dysgenesis,
hydro–cephalus, chronic infections and inammation, as well as
abnormalities in pheromone sensory pathways; however, did not
show any increase susceptibility to cancer (Yang et al, 2000).
HUMAN p53 ISOFORMS
We recently established that human p53 gene has indeed a dual
gene structure similar to p73 and p63 genes (Bourdon et al, 2005).
p53 gene transcription can be initiated in normal human tissue
from two distinct sites upstream of exon1 and from an internal
promoter located in intron 4 (Figure 3A). The alternative promoter
leads to the expression of an N-terminally truncated p53 protein
initiated at codon 133 (D133p53). The intron 9 can be alternatively
spliced to produce three isoforms: p53, p53b (identical to p53i9)
and p53g, where the p53b and p53g isoforms lack the oligomerisa-
tion domain. Therefore, the human p53 gene can encode at least
nine different p53 protein isoforms, p53, p53b, p53g, D133p53,
D133p53b and D133p53g due to alternative splicing of the intron 9
and usage of the alternative promoter in intron 4, and also D40p53,
D40p53b, D40p53g due to alternative splicing of the intron 9 and
alternative initiation of translation or alternative splicing of the
intron 2 (Ghosh et al, 2004) (Figure 3). p53 variant mRNA are
expressed in several normal human tissues in a tissue-dependent
manner, indicating the internal promoter and the alternative
splicing of p53 can be regulated. Moreover, the tissue-specific
expression of the p53 isoforms could explain the tissue-specific
regulation of p53 transcriptional activity in responses to stresses
such as ionising radiation, UV, pH and hypoxia. Thus, the liver
induces p21 and cell-cycle arrest in a p53-dependent manner,
whereas the spleen and thymus induce a massive p53-dependent
apoptosis in response to the same dose of ionising radiation.
(Midgley et al, 1995; Bouvard et al, 2000; Fei et al, 2002).
We have shown using commonly available p53 antibodies that
endogenous p53 isoforms are expressed at the protein level.
However, such antibodies cannot identify specifically the p53
isoforms. It is only by raising a specific anti-p53b antibody that we
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Figure 1 Human p63. (A) Schema of the human p63 gene structure: alternative splicing (a, b, g) and alternative promoters (P1 and P2) are indicated. (B)
p63 protein isoforms: TAp63 proteins encoded from promoter P1 contain the conserved N-terminal domain (FxxcW) of transactivation (TA). DNp63
proteins encoded from promoter P2 are amino-truncated proteins containing an N-terminal domain different from TAp63 proteins. Numbers indicate the
exons encoding p63 protein isoforms.
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protein isoforms. This implies that p53g, D133p53g and D133p53
are expressed at the protein level. P53 isoforms have different
subcellular localisations, suggesting that they can have distinct
activities. Like full-length p53, D133p53 and p53b are localised
mainly in the nucleus with a minor staining in the cytoplasm. In
most cells, p53g is localised in the nucleus, but can be localised in
the cytoplasm in some cells, suggesting that p53g could be
shuttling between the nucleus and the cytoplasm. In most cells,
D133p53b protein is localised in the nucleus and the cytoplasm,
but can form in 10% of cells foci in the nucleus that are different
from nucleoli. Contrary to D133p53b, D133p53g is localised only in
the cytoplasm, indicating that the C-terminal amino acids (b and
g) can modify the subcellular localisation of these isoforms
(Bourdon et al, 2005).
Interestingly, the dual gene structure of the p53 gene is
conserved in human, Drosophila (Bourdon et al, 2005), mouse
(Bourdon, unpublished data) and zebrafish (Chen et al, 2005),
whereas the alternative splicing is species-specific. It suggests an
unforeseen complex regulation that may play a major role in
controlling p53 activity. Like p63 or p73 isoforms, p53 isoforms
can have distinct biochemical activities.
p53b binds preferentially the p53-responsive promoters p21 and
Bax rather than Mdm2, whereas p53 binds preferentially to Mdm2
and p21 rather than Bax promoters. p53b can form a protein
complex with p53 and can specifically enhance p53 transcriptional
activity at the Bax promoter in response to cellular stress, whereas
it has no effect on p53 activity in absence of stress (Bourdon et al,
2005). Co-transfection of p53 with p53b increases slightly p53-
mediated apoptosis, whereas co-transfection of p53 with D133p53
strongly inhibits p53-mediated apoptosis in a dose-dependent
manner. This indicates that wild-type p53 activity may be
modulated in the presence of p53 isoforms, and thus that
regulation of p53 function in normal and tumour tissues in
human is likely to be more complex than has been hitherto
appreciated. Moreover, each p53 protein isoform may have specific
biological activities independent of full-length p53. This may
explain how p53 can be involved in the regulation of so many
biological functions (i.e. cell-cycle arrest, apoptosis, differentia-
tion, replication, DNA repair, meiosis, mitosis, etcy).
Deregulation of p53 isoforms expression may play a role early in
tumour formation, as attenuation of the WT p53 response would
render the cells more susceptible to further genetic damage and
therefore to neoplastic transformation and tumour progression.
Tumours with abnormal p53 isoform expression would have a
predicted phenotype of WT p53 by sequence but compromised p53
activity. Such hypothesis is consistent with experimental evidences
showing abnormal expression of p53 isoforms in head and neck,
acute myeloid leukaemia (AML) and breast tumours (Bourdon
et al, 2005; Anensen et al, 2006; Boldrup et al, 2007). Whereas only
25% of breast tumours express mutant p53, p53b and p53g
expressions are frequently lost (60%) and D133p53 is frequently
overexpressed in breast tumours. The abnormal p53 isoforms
expression can therefore account for loss of p53 tumour
suppressor activity in breast tumour. In AML, where p53 gene is
mutated only in 10% of the cases, abnormal p53 isoform
expression at the mRNA and protein levels has been reported
(Anensen et al, 2006). The authors studied p53 isoform expression
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Figure 2 Human p73. (A) Schema of the human p73 gene structure: alternative splicing (a, b, g, z, D, e, Z) and alternative promoters (P1 and P2) are
indicated. (B) p73 protein isoforms: TAp73 proteins encoded from promoter P1 contain the conserved N-terminal domain (FxxcW) of transactivation
(TA). Ex2p73 proteins are due to alternative splicing of exon 2. They have lost the conserved N-terminal domain (FxxcW) of transactivation (TA), but still
contain part of the transactivation domain (Exon-3). Ex2/3p73 proteins are due to alternative splicing of exons 2 and 3. They have entirely lost the TA
domain and are initiated from exon 4. To our knowledge, the protein encoded by DN’p73 mRNA has not been described. DN’p73 variant is often
overexpressed at the mRNA level in tumours. DN’p73 is due to alternative splicing of exon 30 contained in intron 3. Theoretically, DN’p73 mRNA would
encode either for a short p73 protein or p73 protein isoforms identical to DNp73. DN’p73 mRNA contains the normal initiation site of translation in exon 2
(ATG in perfect kozak sequence) and a stop codon in exon-30. Therefore, it could encode for a short p73 protein composed only of the transactivation
domain (FxxcW). It is possible that translation of DN’p73 mRNA is initiated from the third ATG available present in exon 30and leading to p73 protein
identical to DNp73 protein isoforms. DNp73 proteins encoded from promoter P2 are amino-truncated proteins containing an N-terminal domain different
from TAp73 proteins. Numbers indicate the exons encoding p73 protein isoforms.
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sional immunoblot. They reported a rapid shift within 4h after
chemotherapy from a shorter p53 protein isoform toward full-
length p53 protein expression in AML patient, indicating that
expression of p53 protein isoform could be modulated in vivo in
response to chemotherapy.
This strongly suggests that the differential expression of p53
isoforms could disrupt the p53 response and contribute to tumour
formation (Anensen et al, 2006). Moreover, it may provide some
explanation to the difficulties in many clinical studies to link p53
status to the biological properties and drug sensitivity of human
cancers as p53 status is determined either by sequencing and/or
immunohistochemistry.
Dp53 ISOFORMS
It has recently been reported the intra-exons splicing of the exons
7t o9o fp53, which leads to a p53 isoform deleted of the conserved
box V in the DNA-binding domain (Dp53) (Rohaly et al, 2005).
This noncanonical splicing is not consistent with any known rules
of splicing, which are strictly conserved through eukaryotes (from
yeast to human) (Stamm et al, 2005). Dp53 mRNA was isolated
after reverse transcription at 371C using MMLV reverse tran-
scriptase. Based on our experience, such conditions give rise to
cDNA with noncanonical intra-exons splicing after RT-PCR
amplification probably because mRNA stem–loop structures are
not destroyed at 371C. As we perform reverse transcription at 451C
using AMV reverse transcriptase, we have never amplified cDNA
with noncanonical intra-exons splicing. Despite all our efforts, we
could not detect by RT-PCR, the mRNAs of Dp53 or of its
theoretical spliced variant Dp53b, Dp53g, D133Dp53, D133Dp53b
and D133Dp53g in 21 normal human tissue analysed nor in
numerous tumours of several human tissue origins. Several studies
have already confirmed detection and abnormal expression of
p53b, p53g, D133p53, D133p53b and D133p53g in head and neck
tumours (Boldrup et al, 2007), AML (Anensen et al, 2006) and in
cell lines (Goldschneider et al, 2006). However, none of those
studies reported detection of the Dp53 mRNA, although the
primers used would have allowed its amplification by PCR.
Then, Rohaly et al (2005), attempt to demonstrate endogenous
Dp53 protein expression using a panel of p53 monoclonal
antibodies, DO-1 (epitope 21–25aa), ICA-9 (epitope 383–393aa)
and DO-12 whose epitope (256–270aa) is lost in Dp53 protein.
The author could detect a p53 band at 45kDa with DO-1 and
ICA-9 antibodies but not with DO-12 antibody, which was
interpreted as proving the expression of the Dp53 isoform.
However, this should be interpreted with cautious, as we showed
that p53b, p53g and D40p53 migrate all at 45kDa (Bourdon et al,
2005). In our hand, we can detect p53b, p53g and D40p53 at 45kDa
with DO-12 antibody after long exposure. It is thus likely that
Rohaly et al’s (2005) experimental conditions were not optimised
to detect the 45kDa band (i.e. short exposure, high antibody
dilution,y). Therefore, the 45kDa band identified by Rohaly et al
(2005) is probably composed of a mix of Dp53, p53b, p53g and
D40p53.
To further confirm that the 45kDa band is Dp53 isoform,
Rohaly et al (2005) immunoprecipitated the 45kDa band using p53
antibody and analysed it by MALTI-TOF/MS mass spectrometry.
The masses of the tryptic fragments obtained from MALTI-TOF/
MS were compared to the predicted p53 tryptic peptide map by
peptide mass fingerprinting using database-matching procedure.
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Figure 3 Human p53. (A) Schema of the human p53 gene structure: Alternative splicing (a, b, g) and alternative promoters (P1, P10 and P2) are indicated.
p53 protein isoforms: (B) p53, p53b and p53g proteins encoded from P1 or P10 promoters contain the conserved N-terminal domain (FxxcW) of
transactivation (TA). D133p53 isoforms encoded from promoter P2 are amino-truncated proteins deleted of the entire TA domain and deleted of part of
the DNA-binding domain. Translation is initiated at ATG-133. D40p53 protein isoforms encoded from P1 or P10 promoters are amino-truncated proteins
due to alternative splicing of exon 2 and/or alternative initiation of translation at ATG-40). D40p53 protein isoform have lost the conserved N-terminal
domain of transactivation (FxxcW), but still contain part of the transactivation domain. Dp53 protein isoform is due to noncanonical alternative splicing
between the exon 7 and 9. Dp53 has lost 66 residues including the highly conserved domain V of the DNA-binding domain. The isoforms Dp53b, Dp53g,
D40Dp53, D40Dp53b, D40Dp53g, D133Dp53, D133Dp53b and D133Dp53g should theoretically be generated.
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covered 88% of the p53 protein sequence, confirming that the
45kDa band is composed of p53 protein. The same tryptic
fragments that did not match full-length p53, are encountered in
the predicted Dp53 tryptic peptide map, but are also encountered
in a mix of the predicted p53b and D40p53 tryptic peptide maps.
As the authors did not sequence the corresponding peptides, it
is thus impossible to establish whether Dp53 is expressed. Only
an antibody specific to Dp53 would prove unequivocally the
endogenous expression of Dp53.
Dp53, which lacks a conserved domain of p53 in the DNA-
binding domain, was reported to be transcriptionally active toward
some p53 target genes and to be critical for the intra-S phase
checkpoint (Rohaly et al, 2005). Contrary to previous publication,
Chan and Poon (2007) recently reported with strong experimental
evidences that Dp53 isoform lacks intrinsic transcriptional activity
and lacks dominant-negative activity toward full-length p53. This
is probably because Dp53 is not imported into the nucleus and stay
in the cytoplasm. Therefore, further studies will be required to
establish expression of the endogenous Dp53 isoforms and its
biological relevance.
DETERMINATION OF p53 STATUS BY SEQUENCING
The difficulty to link p53 mutation status to clinical outcome and
cancer treatment can be explained by the fact that mutations of the
p53 gene do not necessarily result in inactivation of p53
transcriptional activity (Kato et al, 2003; Iacopetta et al, 2006;
Petitjean et al, 2007b). Hence, 60% of the mutations that can occur
in the p53 gene do not alter p53 transcriptional activity. Only 15%
of the mutations lead to mutant p53 completely inactive in
transactivation. In the remaining 25%, mutants p53 present
differential transcriptional activity. They can transactivate some
promoters, but are completely inactive on others. It is therefore
important to establish whether p53 mutation is correlated to loss
of p53 function to determine accurately p53 status in clinical
studies.
Moreover, p53 mutation analysis has to be re-evaluated in
cancer in light of p53 isoform expression. p53 isoforms are
encoded by exons different from full-length p53, mutations
occuring upstream of codon 133 (exon-5) or downstream of
codon 331 (exon-9), would affect some p53 isoforms, but not
others. This may lead to the loss of some p53 biological activities,
keeping others unaffected. Furthermore, although p53 gene
mutated at codon 133 substituting methionine to valine, leucine
or isoleucine encodes for a p53 protein with similar transcriptional
activity to wild-type p53, such a mutation prevents initiation of
translation and thus expression of D133p53, D133p53b and
D133p53g isoforms (Kato et al, 2003; Iacopetta et al, 2006;
Petitjean et al, 2007b). Similarly, mutations in introns of p53 gene
can alter p53 activity either by affecting alternative splicing or by
altering the activity of the internal p53 promoter located in intron
4. As p53 isoform can modulate p53 transcriptional activity and
p53-mediated apoptosis, the ratio between p53 isoforms can be an
important cell fate determinant. The changes upon stimuli of the
balance and interactions between the isoforms are likely to be
fundamental to our understanding in the transition between
normal cell cycling and the onset of tumour formation.
DETERMINATION OF p53 STATUS BY
IMMUNOSTAINING
p53 immunostaining on tumour sections should be interpreted
with cautious, as commonly available p53 antibodies can detect
some p53 isoforms, but do not identify them specifically (Table 1).
The mouse monoclonal antibodies DO-1 and DO-7 recognise p53,
p53b and p53g, but not the other p53 isoforms. The rabbit or sheep
polyclonal p53 antibodies (CM1, SaPu, respectively) raised against
recombinant full-length human p53 protein recognise all p53
isoforms, although D133p53b and D133p53g are weakly revealed
by polyclonal antibodies as these isoforms have lost most
immunogenic domains of p53. The mouse monoclonal antibody,
1801, can reveal specifically most p53 isoforms except D133p53,
D133p53b and D133p53g. The mouse monoclonal antibody DO-12
has a weak affinity for p53 and requires a long exposure to reveal
p53 isoforms. However, DO-12 is particularly efficient to
immunoprecipitate D133p53, D133p53b and D133p53g isoforms,
which can be revealed by CM1 rabbit polyclonal antibody. The
421 mouse monoclonal antibody has also a low affinity for p53
mostly, because its epitope can be heavily modified by phosphory-
lations, ubiquitinylation, acetylation, methylation and neddylation.
Although the 421 epitope is present in D40p53 and D133p53
isoforms, we have never been able to detect these isoforms using
the 421 antibody. The rabbit polyclonal KJC8 antibody is specific
of p53b isoforms and can be used in paraffin-embedded tissue.
Novel specific p53 isoforms antibodies are being generated and
will allow a clear identification of the p53 isoforms in the near
future.
p53 isoforms have different subcellular localisations. Therefore,
the use of a panel of p53 antibodies in immunohistochemistry can
give different staining patterns for p53 in a same tumour sample. It
would be interesting to investigate whether some p53 subcellular
localisation can be associated with clinical markers. To have a
better understanding of p53 immunostaining, it should be
completed by RT-PCR analysis to determine p53 isoform mRNA
expression in tumours.
Detection of p53 isoform expression by RT-PCR requires high-
quality RNA. As RNAs are rapidly degraded in tissue in absence of
blood supply (half-life of 15min), RNAs have to be extracted
immediately after biopsies or after surgical resection or on tumour
samples nitrogen-frozen immediately after surgical resection. After
purification, only total RNA extracts presenting a suitable ratio
28S/18SX1.5 should be used for RT-PCR to determine p53 isoform
expression in tumours. Such RNA quality is very difficult to obtain
Table 1 p53 isoform-specific antibodies
Mouse monoclonal Rabbit polyclonal
Epitope (aa) DO-1/DO-7 (20–25) 1801 (46–55) DO-12 (256–270) 421 (372–382) KJC8 (b) CM1 recomb p53
p53 ++ ++ + +   +++
p53b ++ ++ +   ++ ++
p53g ++ ++ +    ++
D40p53   ++ +    ++
D40p53b   ++ +   ++ ++
D40p53g   ++ +    ++
D133p53    +    +
D133p53b    ++   ++ +
D133p53g    ++    +
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destroys low abundant mRNA. Therefore, it is not recommended
to use paraffin-embedded sections as source of RNA for RT-PCR of
p53 isoform.
Therefore, determination of p53 status in clinical studies is
much more complex than hitherto appreciated. It suggests that it
requires an integrated and complex analysis of p53 isoform
expressions associated with p53 mutation analysis and immuno-
histochemistry. To date, no clinical studies have integrated all
those p53 parameters to determine p53 status. Several clinical
studies attempted to establish p53 status by analysing p53 target
gene expression either by immunostaining or RNA microarray.
Unfortunately, there are no established gene or protein markers of
p53 functional activity yet. However, one can expect that future
studies will be able to identify some. It would simplify greatly the
determination of p53 status in tumours and help to diagnosis and
cancer treatment.
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